- Home
- NTB vs DNLI Comparison
NTB vs DNLI Comparison
Compare NTB & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTB
- DNLI
- Stock Information
- Founded
- NTB 1858
- DNLI 2013
- Country
- NTB Bermuda
- DNLI United States
- Employees
- NTB N/A
- DNLI N/A
- Industry
- NTB Commercial Banks
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NTB Finance
- DNLI Health Care
- Exchange
- NTB Nasdaq
- DNLI Nasdaq
- Market Cap
- NTB 1.8B
- DNLI 2.1B
- IPO Year
- NTB 2016
- DNLI 2017
- Fundamental
- Price
- NTB $42.48
- DNLI $13.89
- Analyst Decision
- NTB Buy
- DNLI Strong Buy
- Analyst Count
- NTB 4
- DNLI 15
- Target Price
- NTB $44.25
- DNLI $33.85
- AVG Volume (30 Days)
- NTB 143.8K
- DNLI 1.6M
- Earning Date
- NTB 07-21-2025
- DNLI 07-31-2025
- Dividend Yield
- NTB 4.14%
- DNLI N/A
- EPS Growth
- NTB 7.68
- DNLI N/A
- EPS
- NTB 4.81
- DNLI N/A
- Revenue
- NTB $585,277,000.00
- DNLI N/A
- Revenue This Year
- NTB $3.10
- DNLI N/A
- Revenue Next Year
- NTB $0.34
- DNLI $335.74
- P/E Ratio
- NTB $8.80
- DNLI N/A
- Revenue Growth
- NTB 1.89
- DNLI N/A
- 52 Week Low
- NTB $33.04
- DNLI $10.57
- 52 Week High
- NTB $43.85
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- NTB 53.42
- DNLI 45.02
- Support Level
- NTB $41.67
- DNLI $14.19
- Resistance Level
- NTB $42.79
- DNLI $14.88
- Average True Range (ATR)
- NTB 0.63
- DNLI 0.77
- MACD
- NTB -0.19
- DNLI -0.03
- Stochastic Oscillator
- NTB 44.48
- DNLI 34.55
About NTB Bank of N.T. Butterfield & Son Limited (The) Voting
Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.